Grifols has announced positive results from its phase 2/3 clinical trial evaluating the efficacy and safety of intravenous ...
Topline data were announced from a phase 2/3 trial evaluating Flebogamma 5% DIF (immune globulin intravenous ) in patients with post-polio syndrome (PPS).
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback